Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Tuberculosis TB remains a major global health issue with over 3 million undiagnosed cases and 1 million deaths annually. This research aims to improve TB diagnosis by evaluating faster, simpler, and less expensive point-of-care tests that do not rely on sputum samples. The study focuses on adolescents and adults with symptoms or risk factors for TB presenting at outpatient clinics in high-burden countries. Participants will be tested using novel TB triage and diagnostic tools, including tongue swab-based molecular assays designed for near point-of-care use. The study will compare these new tests against established methods like sputum Xpert MTBRIF Ultra and mycobacterial culture. Additionally, the usability and acceptability of these tests will be assessed by observing and surveying health workers involved in routine TB testing. Participants will undergo screening for TB symptoms or risk factors and provide samples for diagnostic testing. Researchers will evaluate how often the new tests correctly identify TB cases and non-cases over two years. Health workers will be surveyed to understand the ease and practicality of using the new tests. The study is expected to continue until September 2028, with ongoing monitoring of test performance and user feedback.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating new diagnostic tests to improve the detection and management of tuberculosis TB, a disease that leaves many undiagnosed and causes significant mortality worldwide. This study, known as the Rapid Research in Diagnostics Development for TB Network R2D2 TB Network, aims to assess early-stage TB triage, diagnostic, and drug resistance tests in real-world clinical settings across multiple countries. The goal is to identify faster, simpler, and less expensive tools to reduce the current gaps in timely TB diagnosis and treatment initiation. The study involves testing various novel diagnostic methods, including sputum-based and non-sputum biomarker tests, molecular assays, breath-based tests, and artificial intelligence tools to analyze images and sounds related to TB diagnosis. These tests will be compared to established reference standards like sputum culture and molecular resistance testing. The study also evaluates the usability of these tests through observations and surveys of health workers. Participants include adults with symptoms or risk factors for TB, and patients with rifampin-resistant TB for drug susceptibility test evaluations. Participants will undergo diagnostic testing and clinical assessments, with follow-up visits scheduled to monitor test performance and usability. Researchers will measure the sensitivity and specificity of these novel tests over a seven-month period. The study also tracks the ability of health workers to effectively use the new diagnostic tools. Overall participation duration varies by individual, and the study aims to provide comprehensive data to enhance TB diagnosis and treatment worldwide.